10q10k10q10k.net
ARGENX SE

ARGENX SEARGXEarnings & Financial Report

Nasdaq · pharmaceutical industry

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Q4 2025Q2 2025Q4 2024Q2 2024Q2 2023Q2 2022

Revenue

$901.9M

Gross Profit

$806.4M

Operating Profit

$-138.9M

Net Profit

$-32.5M

Gross Margin

89.4%

Operating Margin

-15.4%

Net Margin

-3.6%

YoY Growth

76.5%

EPS

$-0.55

Financial Flow

ARGENX SE Q2 2024 Financial Summary

ARGENX SE reported revenue of $901.9M (up 76.5% YoY) for Q2 2024, with a net profit of $-32.5M (up 73.6% YoY) (-3.6% margin). Cost of goods sold was $95.6M, operating expenses totaled $945.3M.

Key Financial Metrics

Total Revenue$901.9M
Net Profit$-32.5M
Gross Margin89.4%
Operating Margin-15.4%
Report PeriodQ2 2024

ARGENX SE Quarterly Revenue & Net Profit History

ARGENX SE results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 2025$2.5B+83.2%$877.2M35.5%
Q2 2025$1.8B+96.7%$414.8M23.4%
Q4 2024$1.4B—$865.6M64.1%
Q2 2024$901.9M+76.5%$-32.5M-3.6%
Q2 2023$510.9M+337.9%$-123.2M-24.1%
Q2 2022$116.7M-76.6%$-435.9M-373.7%

Income Statement

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Revenue$116.7M$510.9M$901.9M$1.35B$1.77B$2.47B
YoY Growth-76.6%337.9%76.5%N/A96.7%83.2%

Balance Sheet

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Assets$3.25B$3.19B$4.80B$6.20B$7.18B$8.68B
Liabilities$279.0M$335.7M$534.3M$704.2M$1.08B$1.36B
Equity$2.97B$2.86B$4.26B$5.50B$6.10B$7.32B

Cash Flow

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Operating CF$-494.5M$-285.4M$-124.7M$41.9M$361.8M$323.3M